Developing a new drug is a long-term, costly process that requires the cooperation of specialists from many fields. Pharmaceutical and biotechnology companies need access to appropriate laboratory infrastructure, advanced technologies, and teams capable of conducting and interpreting research at successive stages of potential therapy development.
Selvita addresses this need by carrying out both individual studies and comprehensive research programs. Its scope of activity includes, among others, medicinal chemistry, biology, pharmacology, drug metabolism studies, bioanalysis, toxicology, analytical method development, and research on small molecules and biological drugs.
Thanks to this model, companies working on new therapies can utilize specialized research facilities without having to independently build all competencies and laboratories. This allows for more efficient analysis of results, decision-making regarding further project development, and risk reduction at subsequent stages.